PixarBio Corp. Discusses NeuroRelease™ a Non-Addictive Morphine Replacement at the 2016 NYSORA 15th Annual Symposium in New...
September 24 2016 - 9:56AM
Business Wire
PixarBio Corporation today announced they will be discussing
NeuroReleaseTM, a potential breakthrough morphine replacement,
non-opiate/opioid, non-addictive pain treatment at the 2016 NYSORA
15th Annual Symposium in New York City on September 23 - 25, 2016.
PixarBio Chief Commercial Officer David Kaplan, Chief Technology
Officer Dr. Jason Criscione, and Neuroscience Lead Dr. Dana Tilley
will be available to discuss the NeuroRelease Platform.
The NeuroReleaseTM Platform: Non-Addictive and
Non-opiate Treatment of Pain
NeuroReleaseTM is a morphine replacement, and non-addictive pain
platform for the surgical/hospital setting, for the battlefield, or
for acute and chronic pain. First product FDA approval for the
platform will be for a 14-day post-surgical pain treatment and it
is expected in late 2018.
Major Benefits of NeuroReleaseTM
- Effects only sensory signals
- No effect on locomotion nerve fibers,
so patients can enter physical therapy quickly
- Maintains two-point discriminate touch
so patients can function
- No effect on proprioception so no
effect on a person feeling of well-being
Therefore, patients will maintain two-point discriminate touch,
control of their locomotion nerve fibers so they control voluntary
movement to enter rehabilitation quickly with a non-addictive
morphine replacement. PixarBio’s NeuroReleaseTM pain platform also
includes 4-8 hour, 3-day, 7-day, 14-day and 90-Day pain treatments
all have expected FDA approvals in 2020. NeuroReleaseTM is
biodegradable, and it's non-toxic so NeuroReleaseTM can be
re-injected to extend treatment timelines.
PixarBio Corporation has completed the acquisition of a public
entity, and Frank Reynolds is the CEO of the entity. We expect
PixarBio Corporation to begin trading on the OTC-QB in early
October 2016.
PixarBio Corporation was awarded the Boston Business Journal's
"2016 Best Places to Work". The award recognizes PixarBio as one of
the region's best firms, offering the greatest professional
opportunities and work environments to innovate.
About the NYSORA 15th Annual Symposium in New York
City
The New York School of Regional Anesthesia (NYSORA, Inc) is an
educational organization based in New York, NY. NYSORA is a
World-Renowned anesthesia teaching program focused on advancing and
promoting the practice of Regional Anesthesia. For more information
about the NYSORA 15th Annual Symposium visit:
http://nysorasymposium.com/about/
About PixarBio Corporation
PixarBio is a specialty pharmaceutical/biotechnology company
focused on pre-clinical and commercial development of novel
neurological drug delivery systems for post-operative pain.
PixarBio researches and develops targeted delivery systems for
drugs, cells, or biologics to treat pain, epilepsy, Parkinson’s
disease, and spinal cord injury. Our lead product platform,
NeuroRelease™, has achieved sustained therapeutic release of
non-opiate drugs for post-operative, acute and chronic pain in
pre-clinical models. For more information, visit
www.pixarbio.com.
Safe Harbor Statement
This announcement includes “forward-looking statements” within
the meaning of the safe harbor provisions of the United States
Private Securities Litigation Reform Act of 1995. These statements
are based upon the current beliefs and expectations of PixarBio’s
management and are subject to significant risks and uncertainties.
If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of Biotech and medical device industry regulation and
health care legislation in the United States and internationally;
global trends on cost containment; technological advances, new
products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory
approval; PixarBio’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of PixarBio’s patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
PixarBio Corp undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be obtained through PixarBio’s Corp
HQ at 200 Boston Ave, Suite 1875 in Medford, MA 02155. PixarBio
Corp is a private corporation.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160924005016/en/
PixarBio CorporationFrank Reynolds617-803-8838Chief Executive
Officerinfo@pixarbio.com